AKP Stock Overview
A joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Anika Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$15.90 |
| 52 Week High | US$26.40 |
| 52 Week Low | US$15.00 |
| Beta | 0.86 |
| 11 Month Change | -30.26% |
| 3 Month Change | -29.02% |
| 1 Year Change | -18.46% |
| 33 Year Change | -54.05% |
| 5 Year Change | -68.51% |
| Change since IPO | 228.21% |
Recent News & Updates
Recent updates
Shareholder Returns
| AKP | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.3% | -0.2% | 0.8% |
| 1Y | -18.5% | -16.9% | 9.1% |
Return vs Industry: AKP underperformed the German Biotechs industry which returned -16.9% over the past year.
Return vs Market: AKP underperformed the German Market which returned 9.1% over the past year.
Price Volatility
| AKP volatility | |
|---|---|
| AKP Average Weekly Movement | 9.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AKP's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AKP's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1983 | 357 | Cheryl Blanchard | www.anika.com |
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief.
Anika Therapeutics, Inc. Fundamentals Summary
| AKP fundamental statistics | |
|---|---|
| Market cap | €240.44m |
| Earnings (TTM) | -€93.08m |
| Revenue (TTM) | €156.70m |
1.6x
P/S Ratio-2.7x
P/E RatioIs AKP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AKP income statement (TTM) | |
|---|---|
| Revenue | US$164.17m |
| Cost of Revenue | US$83.93m |
| Gross Profit | US$80.23m |
| Other Expenses | US$177.75m |
| Earnings | -US$97.52m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.66 |
| Gross Margin | 48.87% |
| Net Profit Margin | -59.40% |
| Debt/Equity Ratio | 0% |
How did AKP perform over the long term?
See historical performance and comparison